FDA Grants Fast Track Designation to Sangamo’s Hemophilia A Gene Therapy – Drug Discovery & Development
Drug Discovery & Development |
FDA Grants Fast Track Designation to Sangamo's Hemophilia A Gene Therapy
Drug Discovery & Development Sangamo Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SB-525, the Company's clinical stage cDNA gene therapy candidate for hemophilia A, which is being developed as part of an … Novel Hemophilia A Gene Therapy Gets Fast Track Status FDA grants fast track designation to SB-525 for hemophilia A Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual Meeting of the … |
